Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push

Sobi pens $580M deal for Innate’s skin cancer drug ahead of phase 3 push

  • August 10, 2026

Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.

Leave A Comment

Fields (*) Mark are Required